Company initially targets ‘exosome-based wellness’ after licensing new technologies developed at the University of Texas.
US biotech PranaX Corp has secured an oversubscribed $17 million Series A financing round as it seeks to ramp up its development and commercialization of exosome-based regenerative biologics. The Houston-based company says it is developing “biologically informed” approaches aimed at preserving function, reducing inflammation and supporting healthier aging over time.
Exosomes are tiny vesicles naturally released by cells that carry proteins, lipids and genetic material. Once considered biological debris, they are now understood as powerful mediators of intercellular communication with potential roles in immune regulation, tissue repair and neuronal signaling, and PranaX aims to harness those unique features to promote human healthspan.
“PranaX was founded on the belief that exosomes can redefine how we approach aging and long-term wellness,” said founder and COO Dr Steven J Greco.
The company is built on technology licensed from The University of Texas MD Anderson Cancer Center, in particular a core portfolio of patents spanning exosome manufacturing, engineering and therapeutic applications. The technology was originally developed in the context of a Phase I clinical trial in pancreatic cancer targeting the KRASG12D mutation, believed to be the first FDA-approved study to test mesenchymal stem cell-derived exosomes in humans.
While the research at MD Anderson was oncology-focused, PranaX has secured exclusive rights to apply the manufacturing and engineering approach to non-cancer indications, particularly those linked to aging, inflammation and tissue degeneration. The company has previously indicated its plans to develop GMP-grade stem cell exosome supplements for health and wellness applications, although it has left the door open to clinical programs targeting age-related chronic diseases.
The financing round was backed by a group of unnamed family offices, trusts and individual investors that the company describes as having “deep expertise” in biotech and regenerative medicine. The new funding is intended to help the company expand its research and development, strengthen its scientific and operational infrastructure, deepening strategic partnerships, and accelerate product development and commercialization.
